RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Public ClinicalTrials.gov record NCT06987513. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
RECLAIM STUDY: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pemvidutide in the treatment of AUD in subjects with obesity or overweight. After signing the informed consent form, subjects will be screened and if eligible randomized 1:1 to 1 of the following 2 treatment arms: * Pemvidutide: 2.4 mg SC once weekly * Placebo: Placebo SC once weekly
Study identification
- NCT ID
- NCT06987513
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 100 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 15, 2025 (Actual)
- Primary completion
- Jul 30, 2026 (Actual)
- Completion
- Jul 30, 2026 (Actual)
- Last update posted
- Jul 31, 2026
2025 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Altimmune Clinical Study Site | Los Angeles | California | 90038 | — |
| Altimmune Clinical Study Site | Aurora | Colorado | 80045 | — |
| Altimmune Clinical Study Site | New Haven | Connecticut | 06511 | — |
| Altimmune Clinical Study Site | Fort Myers | Florida | 33912 | — |
| Altimmune Clinical Study Site | University Park | Florida | 34201 | — |
| Altimmune Clinical Study Site | North Canton | Ohio | 44720 | — |
| Altimmune Clinical Study Site | Tulsa | Oklahoma | 74136 | — |
| Altimmune Clinical Study Site | Philadelphia | Pennsylvania | 19104 | — |
| Altimmune Clinical Study Site | Providence | Rhode Island | 02923 | — |
| Altimmune Clinical Study Site | Charleston | South Carolina | 29425 | — |
| Altimmune Clinical Study Site | Charlottesville | Virginia | 22903 | — |
| Altimmune Clinical Study Site | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06987513, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 31, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06987513 live on ClinicalTrials.gov.